Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. director David E. I. Pyott acquired common stock through equity compensation rather than open‑market trading. On April 24, 2026, 1,383 shares of common stock were issued upon settlement of vested Restricted Stock Units (RSUs), with each RSU converting into one share.
The RSUs vested in full on that date, subject to his continuous service. Following these transactions, he holds 1,383 shares directly and 7,991 shares indirectly through the David E.I. Pyott Trust.
Tarsus Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2025 describing its commercial launch and continued development programs.
The company reported net product sales of $451.4M for 2025 and delivered approximately 400,000 bottles during the year; launch-to-date net product sales are reported at $646M. The company notes an aggregate market value of common equity held by non-affiliates of approximately $1.7B as of June 30, 2025, and 42,557,492 shares outstanding as of February 17, 2026.
The report summarizes commercialization progress for XDEMVY (lotilaner ophthalmic solution) 0.25% (FDA approved July 2023, launched August 2023), ongoing clinical programs for TP-04 (ocular rosacea) and TP-05 (Lyme disease prophylaxis), license arrangements with Elanco and GrandPharma, manufacturing reliance on CMOs, and key risks including continued losses, supply dependencies, and reimbursement and market adoption uncertainties.
Tarsus Pharmaceuticals, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 25, 2026. Investors will elect four Class III directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy explains how to attend and vote online and confirms 43,023,959 common shares were outstanding on April 27, 2026. It also outlines board structure, committee memberships, director pay, and a pay-for-performance program for executives, including cash bonuses funded at 108% of target and expanded use of stock options, RSUs, and new performance-based RSUs.
The Vanguard Group filed an Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned of Tarsus Pharmaceuticals Inc common stock and 0% of the class. The filing explains an internal realignment that caused certain subsidiaries to report ownership separately and is signed on 03/27/2026.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan sold 2,989 shares of common stock in an open-market transaction at $66.75 per share on March 20, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the sale, he holds 82,791 shares directly. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those shares.
Seshadri Neervannan reported proposed and completed sales of Common Stock of TARS. The filing lists restricted shares vesting on 03/16/2026 (1,093 shares), 03/17/2026 (1,087 shares) and 03/18/2026 (809 shares). The filing also reports open-market sales during the prior three months of 8,366, 3,125, 3,610 and 4,589 shares on 03/04/2026, 03/17/2026, 03/18/2026 and 03/19/2026, respectively, with aggregate proceeds shown per sale.
Tarsus Pharmaceuticals Chief Human Resources Officer Dianne C. Whitfield reported mandated sales of common stock to cover tax withholding obligations tied to restricted stock unit vesting. Over three days, she sold a total of 12,274 shares in open-market transactions at prices between $67 and $69.42 per share. After these sales, she directly held 35,028 shares of common stock. A footnote explains the transactions were "sell to cover" sales required by the company’s tax policy and were not discretionary trades initiated by her.
Tarsus Pharmaceuticals, Inc. reported that its General Counsel, Bryan Wahl, sold a total of 12,440 shares of common stock over three days at prices between $67.00 and $69.42 per share. According to the footnote, these sales were made solely to cover tax withholding obligations tied to the vesting and settlement of restricted stock units and were mandated by the company’s sell-to-cover election, meaning they were not discretionary trades by Wahl. After these transactions, he holds 63,959 shares of Tarsus common stock directly.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan reported mandatory share sales to cover taxes tied to restricted stock vesting. On March 17–19, 2026, he sold 11,324 shares of common stock in open-market transactions at prices between $67.00 and $69.42 per share. A footnote explains these were issuer-required “sell to cover” trades for tax withholding, not discretionary sales. After the transactions, he directly holds 85,780 shares of common stock. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those securities.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported mandated stock sales tied to tax withholding on vested Restricted Stock Units. Over March 17–19, he sold a total of 13,056 shares of common stock in open-market transactions at prices around $67–$69 per share. According to the footnote, these "sell to cover" trades were required by the company to satisfy tax obligations and were not discretionary investment decisions. After these sales, Mottiwala directly holds 61,480 shares of Tarsus Pharmaceuticals common stock.